Lung in chronic autoimmune diseases and hypersensitivity – how to separate these from idiopathic pulmonary fibrosis

Helmut H. Popper (helmut.popper@medunigraz.at)  
Medical University Graz  https://orcid.org/0000-0003-4970-1265

Elvira Stacher-Priehse  
Institute of Pathology, Asklepios Fachkliniken

Luka Brcic  
Medical University Graz, Diagnostic and Research Institute of Pathology

Florian Rammp  
Clinics of Pneumology and Pneumologic Oncology, Teaching Hospital Munich-Bogenhausen

Andreas Nerlich  
Department of Pathology, Teaching Hospital Munich-Bogenhausen

Research article

Keywords: fibrosing pneumonia, UIP, IPF, chronic autoimmune disease, chronic hypersensitivity pneumonia

DOI: https://doi.org/10.21203/rs.3.rs-279238/v1

License: ☒  This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Lung involvement in autoimmune disease (AID) is not uncommon, and may precede other organ manifestations. The histologic pattern is variable and difficult to interpret. Another problem was recently encountered: chronicity presenting with fibrosing pneumonia. This resulted that patients with chronic AID and usual interstitial pneumonia (UIP) were excluded from antifibrotic therapy. Creating a new category of UIP with autoimmune features (IPAF) for patients with AID enabled treatment for these patients. This however raised the opinion, that a pathological investigation for the underlying disease is not necessary.

Results

We retrospectively evaluated 66 cases of AID, 31 cases of hypersensitivity pneumonias (HP), and 10 clinically confirmed usual interstitial pneumonia/idiopathic pulmonary fibrosis (UIP/IPF) cases. 12 additional cases could not be assigned into any of these categories. Acute AID presented with lymphocytic interstitial pneumonia, immune complex deposition, cytotoxicity for specific cell compartments, and alveolar hemorrhage. Subacute patterns most often presented with organizing pneumonia, whereas chronic pattern most often presented as UIP. Granulomas were present in some patients. UIP pattern was the most common presentation in chronic AID and HP, whereas NSIP was rather rare.

Conclusion

The most important, statistically significant feature differentiating chronic AID or HP, from UIP/IPF are lymphocytic infiltrations into myofibroblastic foci. Other features such as granulomas, Langhans giant cells, and protein deposits were significantly associated with AID and HP, but were not encountered in all cases. This study demonstrated that the morphological analysis can uncover the possible etiology in many cases, and a more specific diagnosis can be provided to the clinicians.

Background

Autoimmune diseases (AID) are heterogenous, some of them affecting joints, others involving blood vessels, and some with quite unspecific clinical symptoms [1–3]. They all have in common a deregulation of the immune system resulting in auto-aggression against normal tissues[4–8]. In some diseases, a clinical diagnosis is usually straight-forward as they present with a typical clinical picture: e.g. of skin affection in lupus erythematosus (LE), joint inflammation in rheumatoid arthritis (RA), or glomerular disease in systemic LE or granulomatosis with polyangitis/Wegener's granulomatosis (GPA). Most of these AIDs can affect the lung. In a minority of cases lung involvement can precede the classical symptoms delaying or impeding the diagnosis[9]. This can result in an undetected and untreated
pulmonary disease, which might progress into chronic AID. Hypersensitivity pneumonia (HP) in the acute stage is easily diagnosed, clinically by an exposure anamnesis and typical undulating symptoms associated with exposure to the allergen, and morphologically by loose peripherally concentrated epitheloid cell granulomas combined with lymphocytic interstitial pneumonia (LIP) dominated by CD\(8^+\) T cells. Due to increased sensitivity of CT scan and awareness of fibrosing pneumonia more biopsies are performed, which results in an increasing detection of chronic AID and HP presenting with lung fibrosis.

Subacute and chronic AID and HP in lung can present with three classic patterns: usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), and organizing pneumonia (OP). Rarely unspecific fibrosis of the lung is seen in this setting[1, 10–15]. UIP is the typical pattern of idiopathic pulmonary fibrosis (IPF), a deadly fibrosing pneumonia with incompletely understood etiology. Some underlying mechanisms have been reported, which might be correlated to morphologic features: continuous toxic injury by tobacco smoke toxins inducing apoptosis of pneumocytes, repair by myofibroblasts, and regeneration, during which some epithelial cells differentiate into senescent cells[16–19]. Factors associated with aging are mutations of telomere maintenance genes[20–22] (hTERT, telomerase), affecting the regenerative capacity, regulators of homeostasis and inflammation[23–25] (surfactant apoprotein genes), contributing to prolonged inflammation, and MUC5B[26, 27]. Mutation in the promoter of MUC5B might be responsible for a reduced mucociliary clearance and probably also disrupts regeneration in the peripheral lung parenchyma[28]. Senescent cells release inflammatory cytokines, stimulate the proliferation of myofibroblasts, and prolong the repair process, finally resulting in fibrosis. What patterns in IPF might be expected from these underlying mechanisms? Toxic injury caused by tobacco smoke products will cause apoptosis of pneumocytes, a denuded basal lamina, and a proliferation of myofibroblasts – inflammatory cells likely will be absent, and only be seen in cystic remodeled areas, due to bacterial colonization. The proliferation of the myofibroblasts is driven by the senescent cells[19].

What about UIP in AID and HP? An UIP pattern has been reported in chronic AID and chronic HP. These chronic stages often clinically cannot be attributed to a specific AID, and a new term, interstitial pneumonia with autoimmune features (IPAF) has been created[29]. In chronic HP the causing allergen can often no longer be identified. Senescence seems to play also a role in these immune diseases[19]. If UIP in IPF can be differentiated from UIP in chronic AID and HP has not been evaluated in larger studies, but it might be of therapeutic and prognostic relevance[1, 12, 14, 30–32]. There are divergent reports about survival of chronic AID or HP with UIP pattern versus IPF[14, 31–35]. In both AID and HP immune cells play a major role by inducing injury to the peripheral lung. As both diseases are, similar to IPF, stepwise progressing, additional features enabling a more detailed and etiology-based diagnosis should be reported. Here we aimed to analyze the different patterns of chronic AID and HP in a retrospective series, and compare this to IPF, to identify features which might allow an etiology-based diagnosis. We believe, a more detailed pathological report over just an UIP pattern report will help in a better stratification of patients and concise discussion within the multidisciplinary team[36].
Methods

Out of 103 cases with autoimmune diseases and 148 cases of chronic HP, 78 cases of AID and 31 cases of HP were retrieved from lung tissue archive of the Institute of Pathology, Medical University of Graz. A total of 119 tissues samples from patients with immune diseases and IPF were selected, for which a clinical diagnosis and clinical response was received either before or after the pathological report was issued. These cases were predominantly consultation cases submitted to one of the authors. All 10 IPF cases came from one institution and were clinically verified (see Suppl.Table 1 for patient characteristics and clinical data).
Table 1
Classification of cases and presence of different patterns, including combinations thereof; abbreviations: AID = autoimmune disease, HP = hypersensitivity pneumonia, RA = rheumatoid arthritis, SSc = systemic sclerosis, SLE = systemic Lupus erythematosus, IPF = idiopathic pulmonary fibrosis, UIP = usual interstitial pneumonia, NSIP = nonspecific interstitial pneumonia, OP = organizing pneumonia, BALT = bronchus associated lymphoid tissue

| Diagnosis                                                                 | Number of cases |
|--------------------------------------------------------------------------|-----------------|
| acute, subacute, and chronic AID                                         | 66              |
| subacute or chronic HP                                                   | 31              |
| IPF                                                                       | 10              |
| Unclassified with respect to AID/HP/IPF                                  | 12              |
| Combinations of patterns in AID                                           |                 |
| UIP only                                                                  | 26              |
| UIP and OP                                                                | 2               |
| UIP and LIP                                                               | 16              |
| NSIP cellular                                                             | 3               |
| NSIP fibrosing                                                            | 1               |
| OP only                                                                   | 5               |
| OP and LIP                                                                | 6               |
| LIP only (acute AID)                                                      | 6               |
| unspecific fibrosis                                                       | 2               |
| BALT Hyperplasia only                                                     | 1               |
| Combinations of patterns in HP                                            |                 |
| UIP only                                                                  | 22              |
| UIP and LIP                                                               | 12              |
| LIP only acute HP                                                         | 4               |
| OP and LIP, subacute HP                                                   | 5               |
| Specified AID                                                             |                 |
| RA                                                                        | 12              |
| SSc                                                                       | 11              |
| Sjo                                                                       | 4               |
**Diagnosis** | **Number of cases**
---|---
SLE | 5
Dermatomyositis | 1
Behcet | 1
Raynaud | 1
Good Pasture | 1
Anti-phospholipid antibody syndrome | 2
AID versus HP | 9, including 1 case each with OP, ACIF, and unspecific fibrosis
AID versus IPF | 3

**Definition of patterns**

UIP was defined by the presence of myofibroblastic foci, fibrosis, cystic remodeling of lung lobules, uninvolved normal lung parenchyma, and peripheral accentuation (temporal and spatial heterogeneity). NSIP pattern was defined by uniform widening of alveolar septa by a mixed lymphocytic and histiocytic infiltration (cellular NSIP) without remodeling, or fibrosis of alveolar septa with residual inflammatory infiltrates (fibrosing NSIP) again without remodeling. Organizing pneumonia (OP) was defined by intraalveolar granulation tissue with newly formed capillaries and inflammatory infiltrates predominantly macrophages, but sometimes with residual granulocytes. LIP, a dominant pattern in immune disorders, is characterized by a diffuse monomorphic infiltration of lymphocytes and plasma cells, with a few scattered immunoblasts, with or without follicular hyperplasia of BALT (bronchus associated lymphoid tissue). In contrast to cellular NSIP, cells of the innate immune system are scarce or absent in LIP. Other features of AID and HP are histiocytic or epitheloid granulomas, amyloid or immune complex deposition with/without complement activation, isolated BALT hyperplasia, lymphocytic bronchitis/bronchiolitis, follicular bronchiolitis, and hemorrhage, often mixed in different proportions. Amyloid was defined by a positive Congo red stain with green birefringency, and in addition by immunohistochemistry for amyloid A or P. Immune complex deposition was verified by a positive immunohistochemical reactions for IGG and activation of complement components 1q, 3c, and 5–9 complex.

The tissues were obtained either by video-assisted thoracoscopic or cryobiopsies. Hematoxylin and Eosin (H&E) stained slides were available in all cases. In several cases immunohistochemistry (IHC) for lymphocyte subtypes was performed, using antibodies for CD3, CD4, CD8, CD20, and rarely for FOXP3 (regulatory T cells). All cases were re-evaluated by HP and ES. The presence or absence of the following patterns were recorded for each case: myofibroblastic foci, cystic remodeling of the peripheral lung lobules, spatial and temporal heterogeneity, fibrosis, lymphocytic infiltrates (including LIP), lymphocytes infiltrating the myofibroblastic foci, hyperplasia of bronchus associated lymphoid tissue (BALT),
histiocytic and/or epitheloid granulomas, isolated Langhans giant cells, amyloid deposition, immune complex deposition, complement activation, vasculitis, hemorrhage, vasculopathy (myxoid changes of the intima with few scattered lymphocytes), vascular sclerosis, neutrophils, eosinophils. Additional features not generally associated with fibrosing pneumonias were also recorded (e.g., bronchial and/or bronchiolar inflammation and pleuritis).

For statistical analysis cases were classified as AID, HP, and IPF. The program Kaleidagraph (Synergy Software, v4.5) was used. A significance was stated, if the p-value was ≤ 0.05.

Results

Study cohort

There were altogether 66 cases with acute, subacute, and chronic AID, 31 cases of subacute or chronic HP, and 10 confirmed UIP/IPF cases. 12 cases could not be assigned into any of these categories (Table 1; more detailed data for each patient are given in Supplementary Table 1.).

Histological Findings in autoimmune disease

In 44 cases an UIP pattern was seen, in two cases combined with OP; in 16 cases UIP was combined with LIP pattern. In 12 cases LIP without UIP was found, in six cases combined with OP (within this group there were acute AIDs); OP alone was seen in 5 cases, in two cases unspecific interstitial fibrosis was seen. In four cases NSIP, one fibrosing, and three cellular were seen. In one case only BALT hyperplasia was found (Table 1).

Out of these 66 cases of AID a more specific diagnosis could be established: RA in 12, systemic sclerosis SSc in 11, SLE in 5, Sjogren’s disease in 4 cases, and one case each for Behcet disease, Raynaud’s syndrome (secondary form), dermatomyositis, and Good Pasture syndrome. In 26 cases AID was clinically confirmed, but without a more specific diagnosis. In one of the cases a combination of SSc and SLE was discussed and in another case either Sjogren’s disease or RA was discussed as a possible diagnosis. There were two cases with an antiphospholipid antibody syndrome. In both a diagnosis of an AID was suggested, and as both presented with alveolar hemorrhage, systemic vasculitis or LE was suggested.

Findings in hypersensitivity pneumonia

In 22 of 31 cases of HP an UIP pattern was seen, which was combined with LIP in 12 cases. Four cases presented with LIP only (acute or recurrent HP), in 5 cases LIP was combined with OP; in 9 cases a differential diagnosis of either AID or HP was rendered, three of them presented with OP, airway centered interstitial fibrosis (ACIF), or unspecific interstitial fibrosis, respectively (Table 1).

Differences of AID versus HP by Immunohistochemistry
In cases of HP and AID, where a sufficient number of lymphocytes could be evaluated, a predominance of CD8+ lymphocytes were seen in HP, whereas in AID CD20+B cells, CD4+, and CD8+ T cells were present; whereas scattered FOXP3+ regulatory T cells were seen in HP, these were scarce in AID (Table 2).

**Table 2**
Features, which are helpful for the differentiation of chronic autoimmune disease and hypersensitivity pneumonia from idiopathic pulmonary fibrosis (presence of feature/pattern = 1, absence = 0); * denotes which of the entities are statistically compared.

| Features                          | AID          | HP           | IPF           | significance                        |
|-----------------------------------|--------------|--------------|--------------|-------------------------------------|
| Lymphocytes in myofibroblastic foci | Yes* (1)     | Yes (1)      | No* (0)      | *P < 0.0001                         |
|                                   | 0.91 ± 0.28  |              | 0.16 ± 0.38  |                                     |
| Lymphocytes in myofibroblastic foci | Yes* (1)     | Yes* (1)     |              | *P = 0.92                           |
| Granulomas or giant cells         | Yes* (1)     | Yes (1)      | No* (0)      | *P = 0.028                          |
|                                   | 0.66 ± 0.47  | 0.28 ± 0.45  |              |                                     |
| Hyperplasia of BALT               | Yes*         | Yes**        | No*          | *AID vs IPF p = 0.001; **HP vs IPF p = 0.023 |
|                                   | 0.48 ± 0.50  | 0.32 ± 0.47  | 0.0          | AID vs HP p = 0.09                  |
| Amyloid or immune complex deposition | Yes*         | No*          | No           | *AID vs HP p = 0.004                |
| Predominance of CD8 lymphocytes   | no           | yes          | no           |                                     |
| Mixed lymphocytic infiltrations (CD4, CD8, CD20) | yes         | no           | no           |                                     |

**Findings in IPF**

All ten cases of IPF showed the typical UIP pattern without pronounced inflammation (Table 2). In 3 additional cases a differential diagnosis of either AID or IPF was rendered - these were cryobiopsy derived tissue samples.

*Different patterns in AID, HP, and IPF (see Tables 2 and 3)*
Table 3
A: Features seen in autoimmune diseases. The more morphologic features are combined, the better the diagnosis can be specified.

| Patterns present | Chronic Rheumatoid arthritis | Chronic SLE | Chronic SSc | Chronic Dermatomyositis | Chronic Sjøgren | Chronic HP |
|------------------|-----------------------------|-------------|-------------|------------------------|-----------------|-----------|
| UIP pattern      | yes                         | no          | yes         | yes                    | no              | yes       |
| NSIP pattern     | yes                         | no          | yes         | yes                    | no              | yes       |
| OP pattern       | yes                         | yes         | yes         | yes                    | yes             | yes       |
| Unspecific Fibrosis | yes               | yes         | no          | yes                    | yes             | no        |
| Lymphocytic infiltrations or LIP | yes | yes | yes | yes | yes | yes |
| Giant cells      | yes                         | no          | no          | yes                    | no              | yes       |
| Lymphoid hyperplasia | yes               | no          | yes         | yes                    | yes             | yes       |
| Epitheloid or histiocytic cell granulomas | yes | no | no | yes | no | yes |
| alveolitis       |                            |             |             |                        |                 |           |
| Amyloid deposition | yes                   | no          | yes         | yes                    | yes             | no        |
| Immune complex deposition | yes | yes | yes | yes | no | no |
| Complement activation | yes | yes | no | no | ? | no |
| Vasculitis       |                            |             |             |                        |                 |           |
| Vasculopathy     | no                          | yes         | yes         | no                     | no              | no        |
| Vascular sclerosis | no                      | no          | yes         | no                     | no              | no        |
| Alveolar hemorrhage, fresh and old | no | yes | no | no | yes | no |
| Neutrophils      | yes                         | yes         | yes         | yes                    | no              | no        |
| Eosinophils      | yes/no                      | no          | no          | yes                    | yes             | yes       |
| Bronchiolitis and/or specific forms thereof | yes | no | yes | yes | yes | yes |
| LE phenomenon    | no                          | yes         | no          | no                     | no              | no        |
Table 3
B: Combinations of features which might allow a more specific diagnosis for certain chronic AIDs

| Chronic RA | UIP, LIP, granulomas, amyloid, CD4/CD8/CD20 present |
|------------|------------------------------------------------------|
| Chronic SLE | arterial thrombosis, hemorrhage, pleuritis, immune complex deposition |
| Chronic SSc | UIP, LIP, hyperplasia of BALT, vasculopathy |
| Chronic/subacute Sjøgren | LIP, OP, lymphoepithelial lesions, CD8 + dominance |
| Behcet disease and other rheumatoid diseases | Fibrosis, granulomas, amyloid deposition, lymphocytic infiltrations |

The presence of lymphocytes infiltrating myofibroblastic foci in AID (Fig. 1) was statistically significant different from IPF (p < 0.0001, Table 2), whereas no significant difference was seen when AID was compared to HP (p = 0.92). Next, we compared the presence of histiocytic/epitheloid cell granulomas and/or Langhans giant cells in AID versus IPF (Fig. 2), which also showed a significant difference (p = 0.028), as granulomas were absent in all IPF cases (Table 2); however, granulomas were present in a minority of AIDs. Granulomas were more often found in HP compared to AID, therefore the presence of Langhans cells or granulomas (Fig. 3) favor HP over AID (p < 0.001). Isolated histiocytic giant cells were more common in HP compared to AID. The presence of hyperplasia of BALT (Fig. 4) was in favor of AID or HP (p = 0.001 and p = 0.023, respectively) when compared to IPF, whereas no significance was seen when AID and HP were compared (p = 0.09; Table 2). There was no deposition of amyloid or autoimmune complexes (Fig. 5) in IPF. When the presence or absence of deposits was compared between AID and HP, this was significant (p = 0.004), because deposits were not seen in HP (Table 2). However, only a small number of AID cases presented with deposits, which explains the p-value. Other features such as chronic bronchitis/bronchiolitis, vasculitis, hemorrhage, and degenerative changes of the intima (vasculopathy) were seen in few cases, therefore due to the small numbers, a statistical analysis was not performed.

In more than half of the cases a more specific diagnosis of AID could be suggested to the clinicians (Table 3AB). Examples were cases of RA presenting with combinations of UIP, LIP, granulomas, and amyloid deposits (Fig. 5, 6). A combination of arterial thrombosis, immune complex deposits, and hemorrhage, sometimes combined with pleuritis pointed to SLE (Fig. 7). In acute juvenile SLE an LE phenomenon could be seen in pleuritis (Fig. 7). An LIP pattern combined with OP and lymphoepithelial lesions with predominant CD8+ Tcells favored Sjøgren's disease (Fig. 8). Finally, UIP combined with LIP, hyperplasia of BALT, and myxoid changes of the intima of pulmonary arteries was suggestive of SSc (Fig. 9). Good Pasture disease could be suggested due to alveolar hemorrhage, fibrosis, and the proof of linear deposits of immunoglobulin at the basal membrane of alveolar septa and capillaries combined with complement activation. A pathological diagnosis of anti-phospholipid syndrome and secondary Raynaud's syndrome was not possible; in Behcet disease a rheumatoid disorder was suggested because of large fibrotic areas, few ill-formed epitheloid cell granulomas, amyloid, and scattered lymphocytic infiltration (Fig. 10).
Discussion

Sorting fibrosing pneumonias into UIP, NSIP, and OP are usually performed in pathological laboratories. The pattern report is further discussed in a multidisciplinary team composed of clinicians, radiologists, and pathologists, proposed by international guidelines[37, 38]. These recommendations suggested not to perform biopsies, when clinical and radiological features were in favor of UIP/IPF. But, new studies showed that radiologic features of UIP are not specific enough to make a diagnosis of IPF. Wright et al evaluated 23 cases, and found that features of peribronchiolar metaplasia and giant cells or granulomas were in favor of HP and excluded IPF – features which can only be evaluated in biopsies[39]. One third of their cases could even not be solved by a multidisciplinary team discussion. Similarly Churg pointed to other features favoring HP over IPF, such as upper-lobe predominance, giant cells or granulomas, and peribronchiolar metaplasia[40]. Not much reports have focused on AID /connective tissue diseases, although patterns seen in chronic AID are very similar to IPF[40]. Even genetic alterations of surfactant and telomerase genes have been reported in AID similar to IPF[41, 42]. Whereas an NSIP pattern almost exclusively is associated with AID or HP, an UIP pattern has a wider range of differentials. Positive antinuclear antibodies (ANA) are not always present in chronic AID, and CT scans might also not always discriminate IPF from AID[43]. If chronic AID with UIP pattern has a better overall survival remains uncertain.

In this study we demonstrated, that a pathological analysis of patterns in addition to UIP, NSIP, or OP can add more information about the underlying etiology. Lymphocytes infiltrating myofibroblastic foci are indicators of an immune disease, either AID or HP. Other combinations of UIP with granulomas and/or histiocytic giant cells, hyperplasia of BALT, and protein deposits are also characteristic for immune disorders. Based on these findings the pathological report can exclude IPF without knowing radiologic and clinical data. The issued report can further strengthen the discussion in a multidisciplinary team to narrow down the differential diagnosis, by including distribution patterns, clinical presentation and laboratory data.

Even more, by including specific patterns in some of the AIDs the pathologic report can provide suggestions for one of the AIDs, as we have shown in roughly 40% of these cases (Table 3). RA with lung involvement can present with LIP in the acute form, but with UIP or NSIP in the chronic and subacute form, often combined with LIP in the former. Granulomas are seen especially in seropositive forms of RA. In chronic RA deposition of immune complexes as well as amyloid is common. Very large idiotypic-antiidotypic immune complexes with granulomatous reaction are most often encountered in RA less in SLE[6, 44, 45]. Therefore, if a combination of these patterns is seen in a biopsy RA can be suggested. Subacute or chronic SLE in the authors experience rarely present with UIP, but often a combination of OP, unspecific fibrosis, thrombosis, and deposition of immune complexes is seen. In SLE these antigen-antibody complexes usually activate complement, which can be proven by IHC. SSc is known for its high numbers of autoantibodies and circulating immune complexes. In our cases an UIP pattern with hyperplasia of BALT, and vasculopathy of the pulmonary arteries, e.g. a concentric deposition of myxoid material and scattered lymphocytes within the intima of pulmonary arteries was commonly seen and did
allow the suggestion of SSc. Sjögren’s disease is characterized by an aggressive lymphocytic infiltration of the mucosa of salivary and lacrimal glands, and also a similar infiltration of the mucosa of bronchi and bronchioles, mimicking lymphoepithelial lesions as seen in MALT lymphomas. A combination of OP and LIP with a CD8+ Tcell infiltration (in our cases) and lymphoepithelial lesions are suggestive for Sjögren’s disease.

Chronic HP can in some instances be differentiated from AID. Protein deposits either immune complexes or amyloid help to rule out HP, whereas scattered giant cells and ill-formed granulomas favor HP. In contrast to other reports, we could not see any significant difference between AID and HP with respect to BALT hyperplasia[46]. NSIP and OP patterns were relatively rare in our cases. NSIP and an isolated OP pattern in all cases were associated with AIDs, similar to previous reports[47]. However, OP pattern was combined with UIP in some cases, and more important LIP was present in several cases with an immune-based etiology.

Since several years cryobiopsies are preferred over open lung biopsies in diagnosing interstitial lung diseases, including fibrosing pneumonias. These biopsies are useful in all cases, where a clinical and radiological diagnosis already favors IPF, AID or HP. However, in those cases with unusual clinical and radiological pattern videothorascopic biopsy is superior and should be considered if the cryobiopsy is not diagnostic. The distribution of patterns as described above can be very focal, involving different lung segments or even lobes. This is also seen on CT scans, where honeycombing might be seen focally, while ground glass opacities are present in other foci. A larger piece of tissue will increase the likelihood of sampling all these different patterns.

**Conclusion**

Here we have shown that a pathological analysis can provide more than just diagnosing IPAF, which does not even include chronic HP. In our diagnostic workup we should try to be as specific as possible, and dig for the underlying etiology. In some cases, we might be able to even discern chronic HP from AID. This might provide additional clues for treatment. Even in those cases, where the pathological report can only exclude IPF this would enable clinicians to investigate additional treatment options.

A multidisciplinary team discussion is recommended by international guidelines[48]. In the view of the authors a biopsy should be performed not only in cases, where CT scan findings are inconclusive[38]. Lynch recommended a re-review of IPF cases on a regular basis, as the diagnosis might change. However, a pathological analysis can provide much more information and might early on help clinicians to better stratify their patients. In our consultation praxis we have seen cases, initially diagnosed as IPF by CT scan and clinical presentation, which later on turned into chronic AID.

**Declarations**
Ethics approval and consent to participate: A consent was not required as the patient data were anonymized. The study was approved by the Ethical Committee of the Medical University of Graz (EK 24-135 ex 11/12).

Helmut Popper can submit the manuscript in behalf of all authors

All data are provided in the method and result section.

The authors declare no conflict of interest associated with this study.

No funding was received for this study.

HP and ESP analyzed the cases and designed the study. LB analyzed some cases. FR and AN provided several cases, and FR did a clinical follow-up study for the IPF cases. HP wrote the draft manuscript, and all authors contributed to the final version.

References

1. Vij R, Noth I, Strek ME: Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011, 140(5):1292-1299.

2. Alhamad EH, Cal JG, Alboukai AA, Shaik SA, Omair MA: Autoimmune symptoms in idiopathic pulmonary fibrosis: Clinical significance. Clinical Respiratory Journal 2016, 10:350-358.

3. Collins BF, Spiekerman CF, Shaw MA, Ho LA, Hayes J, Spada CA, Stamato CM, Raghu G: Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. Chest 2017, 152(1):103-112.

4. Zhang-Hoover J, Stein-Streilein J: Tolerogenic APC generate CD8+ T regulatory cells that modulate pulmonary interstitial fibrosis. J Immunol 2004, 172(1):178-185.

5. Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, Wang Y, Davis RJ, Greenberg PD, Flavell RA, Dong C: Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 2004, 430(7001):793-797.

6. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34(2):501-537.

7. Bluestone JA, Bour-Jordan H, Cheng M, Anderson M: T cells in the control of organ-specific autoimmunity. J Clin Invest 2015, 125(6):2250-2260.

8. Liang Y, Tsoi LC, Xing X, Beamer MA, Swindell WR, Sarkar MK, Berthier CC, Stuart PE, Harms PW, Nair RP et al: A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases. Nat Immunol 2017, 18(2):152-160.

9. Kono M, Nakamura Y, Yoshimura K, Enomoto Y, Oyama Y, Hozumi H, Enomoto N, Fujisawa T, Inui N, Hamada E et al: Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular
10. Yousem SA, Gibson K, Kaminski N, Oddis CV, Ascherman DP: The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Mod Pathol 2010, 23(6):874-880.

11. Romagnoli M, Nannini C, Piciuccci S, Girelli F, Gurioli C, Casoni G, Ravaglia C, Tomassetti S, Gurioli C, Gavelli G et al: Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Eur Respir J 2011, 38(2):384-391.

12. Alhamad EH, Al-Kassimi FA, Alboukai AA, Raddaoui E, Al-Hajjaj MS, Hajjar W, Shaik SA: Comparison of three groups of patients with usual interstitial pneumonia. Respir Med 2012, 106(11):1575-1585.

13. Solomon JJ, Brown KK: Rheumatoid arthritis-associated interstitial lung disease. Open Access Rheumatol 2012, 4:21-31.

14. Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, Curran-Everett D, Fischer A, Swigris JJ, Brown KK: Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013, 107(8):1247-1252.

15. Ferri C, Manfredi A, Sebastiani M, Colaci M, Giuggioli D, Vacchi C, Della Casa G, Cerri S, Torricelli P, Luppi F: Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmun Rev 2016, 15(1):61-70.

16. Selman M, Pardo A: Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis: An integral model. American Journal of Respiratory and Critical Care Medicine 2014, 189:1161-1172.

17. Chilosi M, Carloni A, Rossi A, Poletti V: Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res 2013, 162(3):156-173.

18. Álvarez D, Cárdenes N, Sellarés J, Bueno M, Corey C, Hanumanthu VS, Peng Y, D’Cunha H, Sembrat J, Nouraie M et al: IPF lung fibroblasts have a senescent phenotype. Am J Physiol Lung Cell Mol Physiol 2017, 313(6):L1164-L1173.

19. Gallob F, Brcic L, Eidenhammer S, Rumpp F, Nerlich A, Popper H: Senescence and autophagy in usual interstitial pneumonia of different etiology. Virchows Arch 2020.

20. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, Rosenblatt RL, Girod CE, Garrity ER, Xing C et al: Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS ONE 2010, 5(5):e10680.

21. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM et al: Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008, 105(35):13051-13056.

22. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK: Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007, 104(18):7552-7557.
23. Selman M, Lin HM, Montano M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM et al: Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. *Hum Genet* 2003, 113(6):542-550.

24. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, Markin C, Renzoni E, Lympay P, Thomas AQ et al: Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. *Thorax* 2004, 59:977-980.

25. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, DiMaio JM, Kinch LN, Grishin NV, Garcia CK: Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. *Am J Hum Genet* 2009, 84(1):52-59.

26. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE et al: Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *Jama* 2013, 309(21):2232-2239.

27. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, Airo P, Matucci-Cerinic M, Wallaert B, Israel-Biet D et al: The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. *PLoS One* 2013, 8(8):e70621.

28. Evans CM, Fingerlin TE, Schwarz MI, Lynch D, Kurche J, Warg L, Yang IV, Schwartz DA: Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. *Physiol Rev* 2016, 96(4):1567-1591.

29. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL et al: An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *Eur Respir J* 2015, 46(4):976-987.

30. Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, Curran-Everett D, Gillis JZ, Meehan RT, Brown KK: Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. *Chest* 2008, 134(3):601-605.

31. Moua T, Zamora Martinez AC, Baqir M, Vassallo R, Limper AH, Ryu JH: Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. *Respir Res* 2014, 15(1):154.

32. Chung JH, Montner SM, Adegunsoye A, Lee C, Oldham JM, Husain AN, MacMahon H, Noth I, Vij R, Strek ME: CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. *AJR Am J Roentgenol* 2017, 208(6):1229-1236.

33. Kim HC, Lee JH, Chae EJ, Song JS, Song JW: Long-term clinical course and outcome of interstitial pneumonia with autoimmune features. *Respirology* 2020, 25(6):636-643.

34. Chartrand S, Lee JS, Swigris JJ, Stanchev L, Fischer A: Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. *Lung* 2019, 197(6):709-713.
35. Kamiya H, Panlaqui OM: Systematic review and meta-analysis of the prognosis and prognostic factors of interstitial pneumonia with autoimmune features. *BMJ Open* 2019, 9(12):e031444.

36. Hariri LP, Smith ML, Mino-Kenudson M, Allen TC, Attanoos R, Borczuk A, Burke L, Cagle PT, Capelozzi V, Dacic S *et al.* Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. *Ann Am Thorac Soc* 2020, 17(5):550-554.

37. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F *et al.* Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018, 198(5):e44-e68.

38. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T *et al.* Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med* 2018, 6(2):138-153.

39. Wright JL, Churg A, Hague CJ, Wong A, Ryerson CJ: Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. *Mod Pathol* 2020, 33(4):616-625.

40. Churg A: Centrilobular Fibrosis in Fibrotic (Chronic) Hypersensitivity Pneumonitis, Usual Interstitial Pneumonia, and Connective Tissue Disease-Associated Interstitial Lung Disease. *Arch Pathol Lab Med* 2020, 144(12):1509-1516.

41. Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, Meyer K, Raghu G, Collard HR, Garcia CK: Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. *Eur Respir J* 2016, 48(6):1710-1720.

42. Xue M, Guo Z, Cai C, Sun B, Wang H: Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia. *Respiration* 2019:1-12.

43. Kelly BT, Moua T: Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality. *Respirology* 2018, 23(6):600-605.

44. Hancock WK, Barnett EV: Demonstration of anti-idiotypic antibodies directed against IgM rheumatoid factor in the serum of rheumatoid arthritis patients. *Clin Exp Immunol* 1989, 75(1):25-29.

45. Koopman WJ, Schrohenloher RE: Rheumatoid factor diversity. *In Vivo* 1988, 2(1):73-77.

46. Papiris SA, Tsonis IA, Moutsopoulos HM: Sjögren's Syndrome. *Semin Respir Crit Care Med* 2007, 28(4):459-471.

47. Nicholson AG, Colby TV, Wells AU: Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. *Sarcoidosis Vasc Diffuse Lung Dis* 2002, 19(1):10-17.

48. Smith ML, Hariri LP, Mino-Kenudson M, Dacic S, Attanoos R, Borczuk A, Colby TV, Cooper W, Jones KD, Leslie KO *et al.* Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. *Arch Pathol Lab Med* 2020, 144(12):1477-1489.